Phase 1 Trial Validates Anti-PD-L1 Antibody for Alzheimer’s

HEADLINES

Italian Jewish Teenagers Targeted in Antisemitic Attack at Bulgarian Summer Camp Amid Escalating Hostility Across Europe

Cruz Sounds Alarm on Muslim Brotherhood Network as Democrats Boycott Hearing

Fetterman unloads on El-Sayed

Fetterman unloads on El-Sayed, predicts he could lose Michigan Senate seat for Democrats

Husted joins Moreno in calling for Max Miller to resign

Slotkin joins Cruz, Knott, Suozzi in leading federal buffer zone bill

Trump’s push for a Hormuz deal alarms experts over terms ceding oversight to Iran

SCIENCE & TECHNOLOGY

Phase 1 Trial Validates Anti-PD-L1 Antibody for Alzheimer’s

By Newswire
August 4, 2026

IBC-Ab002, an anti-PD-L1 immunotherapy targeting systemic immune aging, is safe and reduces markers of neuronal damage in Alzheimer’s patients.

SCIENCE & TECHNOLOGY

Brain PET Scans Link Late-Onset Psychosis to Tau and Amyloid

By Newswire
August 4, 2026

A new study using PET imaging reveals that 65% of patients with late-onset psychosis exhibit tau protein buildup in the brain, linking midlife hallucinations and […]

You may choose to prevent this website from aggregating and analyzing the actions you take here. Doing so will protect your privacy, but will also prevent the owner from learning from your actions and creating a better experience for you and other users.